Sobi announces positive results from phase III study of Doptelet (avatrombopag) for treatment of children and adolescents with immune thrombocytopenia
Sobi announced positive results from the AVA-PED-301 study (NCT04516967), evaluating the efficacy and safety of avatrombopag (Doptelet) for the treatment of paediatric patients with immune thrombocytopenia (ITP) of… read more.
